By Manrose Singh, Danny MacKenzie, Sanket Desai, Noelle Batista, and Dong Zhang Since the early 1990s, when telomerase was first cloned, targeting the telomere maintenance mechanism (TMM) to treat cancer has been considered to be a superior strategy to many, yet, almost three decades later, pursuing this strategy has led to no FDA approved oncology drugs.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Manrose
Contact Manrose, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack